Patent intelligence · US
US 11124493
Nuclear transport modulators and uses thereof
Nuclear transport modulators and uses thereof
Patent details — US 11124493
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 21, 2021
- Expiration
- Sep 16, 2041
- Applicant
- Karyopharm Therapeutics Inc.
- Claims
- 10
- CPC classes
- A61P, A61P11/00, A61P17/02, A61P25/00
Quick answer
US 11124493 (Nuclear transport modulators and uses thereof) is held by Karyopharm Therapeutics Inc.. Status: granted. Granted Sep 21, 2021. Expires Sep 16, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Karyopharm Therapeutics Inc.
- Grant date
- Expiration
- Claims
- 10
- CPC classes
- A61P, A61P11/00, A61P17/02, A61P25/00, A61P25/28, A61P27/02
More from Karyopharm Therapeutics Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12371420
Polymorphs of Selinexor
granted -
US 12331040
Substituted benzofuranyl and benzoxazolyl compounds and uses thereof
granted -
US 12318386
Combination of XPO1 inhibitors and second agents for the treatment of prostate cancer
granted -
US 12291508
Hydrazide containing nuclear transport modulators and uses thereof
granted -
US 11945794
Nuclear transport modulators and uses thereof
granted -
US 11807629
Polymorphs of Selinexor
granted -
US 11787771
Hydrazide containing nuclear transport modulators and uses thereof
granted -
US 11753401
Polymorphs of Selinexor
granted
Frequently asked questions
What is US patent 11124493?
US 11124493 (Nuclear transport modulators and uses thereof) is held by Karyopharm Therapeutics Inc.. Status: granted. Granted Sep 21, 2021. Expires Sep 16, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11124493?
Karyopharm Therapeutics Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 38 pharmaceutical patents for this assignee.
When does US 11124493 expire?
Our index shows an expiration date of Sep 16, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.